Trifecta-Kidney cfDNA-MMDx Study (NCT04239703)

🧪 Interventions in This Study

• MMDx (DIAGNOSTIC_TEST)
• Prospera (DIAGNOSTIC_TEST)
• HLA antibody (DIAGNOSTIC_TEST)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. All kidney transplant recipients undergoing a kidney biopsy for clinical indications, as determined by their physician or surgeon, will be eligible to enroll in the study.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (31 Sites)

Showing the first 25 of 31 sites.

• Tampa General Hospital — Tampa, Florida
• University of Maryland School of Medicine — Baltimore, Maryland
• The Johns Hopkins University, School of Medicine — Baltimore, Maryland
• Detroit Medical Center, Harper University Hospital of Wayne State University — Detroit, Michigan
• Henry Ford Hospital — Detroit, Michigan
• Barnes-Jewish Hospital, Washington University at St. Louis — St Louis, Missouri
• University Hospitals Cleveland Medical Ctr. — Cleveland, Ohio
• Cleveland Clinic — Cleveland, Ohio
• Intermountain Transplant Services — Murray, Utah
• Virginia Commonwealth University Medical Center — Richmond, Virginia
• Division of Nephrology & UW Organ Transplant Center University of Washington — Seattle, Washington
• Department of Nephrology, The Royal Melbourne Hospital 1 South East — Melbourne,
• University of Alberta, Department of Medicine — Edmonton, Alberta
• ST. Paul's Hospital, 6A Providence Building, 1081 Burrard Street — Vancouver, British Columbia
• University Hospital Merkur Renal Division — Zagreb,
• Institute for Clinical and Experimental Medicine (IKEM) — Prague,
• Charite-Medical University of Berlin Department of Nephrology — Berlin,
• Centre of Nephrology, Vilnius University Hospital Santaros Klinikos — Vilnius,
• Department of Nephrology and Transplantation Medical University in Bialystok — Bialystok,
• University Hospital nr1 Bydgoszcz, Klinika Transplantologii — Bydgoszcz,
• Medical University of Gdańsk Klinika Nefrologii Transplantologii i Chorób Wewnętrznych — Gdansk,
• Medical University of Silesia — Katowice,
• Department of Transplantation and General Surgery, Wojewodzki Hospital — Poznan,
• Department of Nephrology, Transplantation and Internal Medicine, University Hospital n.2 — Szczecin,
• Pomeranian Medical University, Samodzielny Publiczny Woj. Szpital Zespolony, Oddzial Nefrologii i Transplantacji Nerek — Szczecin,

📞 Contact the Study Coordinator

Phone: (780) 492-1725

Email: konrad@ualberta.ca

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Kidney Transplant Rejection

• Microbiome and Immunosuppression: The Mission Study — Minneapolis, Minnesota
• Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection — Chicago, Illinois
• The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive) — Birmingham, Alabama
• Treatment of Antibody-Mediated Rejection (ABMR) With CarBel — Birmingham, Alabama
• Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring — Los Angeles, California

Explore by condition: All Kidney Transplant Rejection clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.